

Marvel Biosciences Corp.

420 - 505 8th Ave SW
Calgary, AB T2P 1G2



**NOTICE OF CHANGE OF AUDITOR
("Notice")**

MARVEL BIOSCIENCES CORP.

TO: MNP LLP ("**MNP**")

AND TO: BAKER TILLY WM LLP ("**Baker Tilly**")

AND TO: Alberta Securities Commission
British Columbia Securities Commission
Ontario Securities Commission

Notice is hereby given, pursuant to section 4.11 of National Instrument 51-102 – *Continuous Disclosure Obligations* ("**NI 51-102**"), of a change of auditor of Marvel Biosciences Corp. ("**Marvel**" or the "**Company**").

1. MNP (the "**Predecessor Auditor**") was removed as the Company's auditor effective September 3, 2025.
2. The removal of the Predecessor Auditor was considered by the Board of Directors of the Company and the decision to terminate the Predecessor Auditor was approved by the Company's Board of Directors.
3. The Board of Directors of the Company also approved, subject to the applicable regulations, the appointment of Baker Tilly (the "**Successor Auditor**") as auditors of the Company to provide audit services to the Company for the year ending July 31, 2025 and to hold office as auditors of the Corporation until the next annual meeting of shareholders of the Company. The Successor Auditor's appointment was effective **September 18, 2025**
4. MNP's audit reports on the Company's annual consolidated financial statements for the two completed financial years preceding the date of this Notice, being the fiscal years ended July 31, 2024 and July 31, 2023, did not express a modified opinion.
5. There have been no "reportable events" as defined in NI 51-102 involving the Company and MNP in connection with the audits of the Company's two most recently completed financial years or in connection with any subsequent period up to and including **September 18, 2025**

DATED this 18th day of **September**, 2025

MARVEL BIOSCIENCES CORP.

DocuSigned by:

Per: C6058E2F07EC4FE...
J. Roderick Matheson, President, CEO and Director